Photodynamic therapy against cervical intraepithelial neoplasia by talaporfin sodium

Photodynamic therapy against cervical intraepithelial neoplasia by talaporfin sodium - Photodynamic therapy against cervical intraepithelial neoplasia by talaporfin sodium

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021386

Enrollment

Registered

2016-03-08

Start date

2016-03-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical intraepithelial neoplasia (CIN1 - CIN3)

Interventions

Intravenous administration of talaporfin sodium 40mg/m2. After 4 hours administration, we perform irradiation by PD laser.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who have CIN1 - CIN3

Exclusion criteria

Exclusion criteria: The case which has no reported complications

Design outcomes

Primary

Measure	Time frame
The curative ratio of photodynamic therapy by talaporfin sodium against CIN is confirmed at 2 months and 5 months after PDT.	—

Secondary

Measure	Time frame
The side effects of photodynamic therapy by talaporfin are confirmed.	—

Countries

Japan

Contacts

Public ContactMurakami Hirotake

Hamamatsu University School of Medicine Obstetorics and Gynecology

obstslot@hama-med.ac.jp053-435-2309

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026